Radiation therapy for oligometastatic non-small cell lung cancer

Cancer and Metastasis Reviews

Volumn 34, Issue 2, 2015, Pages 183-193

  Salama, Joseph K ^a   Schild, Steven E ^b  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Metastasectomy; Non small cell lung cancer; Oligometastases; Radiotherapy; SBRT

Indexed keywords

MICRORNA;

ARTICLE; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; COMORBIDITY; DISEASE FREE INTERVAL; HUMAN; META ANALYSIS; METASTASIS; NON SMALL CELL LUNG CANCER; NONHUMAN; OLIGOMETASTATIC NON SMALL CELL LUNG CANCER; PATIENT SELECTION; PRIORITY JOURNAL; SYSTEMATIC REVIEW; TUMOR ABLATION; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL (TOPIC); DISEASE COURSE; DISEASE FREE SURVIVAL; LUNG NEOPLASMS; NEOPLASM METASTASIS; PROCEDURES; RADIOSURGERY;

CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; HUMANS; LUNG NEOPLASMS; NEOPLASM METASTASIS; PATIENT SELECTION; RADIOSURGERY;

EID: 84938416010     PISSN: 01677659     EISSN: 15737233     Source Type: Journal    
DOI: 10.1007/s10555-015-9559-z     Document Type: Article

References (50)

1. Peters, S., Adjei, A. A., Gridelli, C., Reck, M., Kerr, K., Felip, E., et al. (2012). Metastatic non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 23(Suppl 7), vii56–vii64. doi:10.1093/annonc/mds226.
2. Scagliotti, G. V., Parikh, P., von Pawel, J., Biesma, B., Vansteenkiste, J., Manegold, C., et al. (2008). Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. Journal of Clinical Oncology, 26(21), 3543–3551. doi:10.1200/JCO.2007.15.0375.
3. Lima, A. B., Macedo, L. T., & Sasse, A. D. (2011). Addition of bevacizumab to chemotherapy in advanced non-small cell lung cancer: a systematic review and meta-analysis. PLoS One, 6(8), e22681. doi:10.1371/journal.pone.0022681.
4. Soria, J. C., Mauguen, A., Reck, M., Sandler, A. B., Saijo, N., Johnson, D. H., et al. (2013). Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer. Annals of Oncology, 24(1), 20–30. doi:10.1093/annonc/mds590.
5. Mok, T. S., Wu, Y. L., Thongprasert, S., Yang, C. H., Chu, D. T., Saijo, N., et al. (2009). Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. New England Journal of Medicine, 361(10), 947–957. doi:10.1056/NEJMoa0810699.
6. Kwak, E. L., Bang, Y. J., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., et al. (2010). Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. New England Journal of Medicine, 363(18), 1693–1703. doi:10.1056/NEJMoa1006448.
7. Shaw, A. T., Ou, S. H., Bang, Y. J., Camidge, D. R., Solomon, B. J., Salgia, R., et al. (2014). Crizotinib in ROS1-rearranged non-small-cell lung cancer. New England Journal of Medicine. doi:10.1056/NEJMoa1406766.
8. Patchell, R. A., Tibbs, P. A., Walsh, J. W., Dempsey, R. J., Maruyama, Y., Kryscio, R. J., et al. (1990). A randomized trial of surgery in the treatment of single metastases to the brain. New England Journal of Medicine, 322(8), 494–500.
9. Kocher, M., Soffietti, R., Abacioglu, U., Villa, S., Fauchon, F., Baumert, B. G., et al. (2011). Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952–26001 study. Journal of Clinical Oncology, 29(2), 134–141. doi:10.1200/JCO.2010.30.1655.
10. Andrews, D. W., Scott, C. B., Sperduto, P. W., Flanders, A. E., Gaspar, L. E., Schell, M. C., et al. (2004). Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet, 363(9422), 1665–1672.
11. Patel, P. R., Yoo, D. S., Niibe, Y., Urbanic, J. J., & Salama, J. K. (2012). A call for the aggressive treatment of oligometastatic and oligo-recurrent non-small cell lung cancer. Pulmonary Medicine, 2012, 480961. doi:10.1155/2012/480961.
12. Lewis, SL., Porceddu, S., Nakamura, N., Palma, D., Lo, S., Hoskin, P., et al. (2014). Definitive stereotactic body radiotherapy (SBRT) for extracranial oligometastases: an international survey of >1000 Radiation Oncologists. American Journal of Clinical Oncology. doi:10.1097/COC.0000000000000169.
13. Hellman, S., & Weichselbaum, R. R. (1995). Oligometastases. Journal of Clinical Oncology, 13(1), 8–10.
14. Rubin, P., & Green, J. (1968). Solitary metastases. Springfield, IL: C. C. Thomas.
15. Cheruvu, P., Metcalfe, S. K., Metcalfe, J., Chen, Y., Okunieff, P., & Milano, M. T. (2011). Comparison of outcomes in patients with stage III versus limited stage IV non-small cell lung cancer. [Comparative Study]. Radiation Oncology, 6, 80. doi:10.1186/1748-717X-6-80.
16. Albain, K. S., Crowley, J. J., LeBlanc, M., & Livingston, R. B. (1991). Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. Journal of Clinical Oncology, 9(9), 1618–1626.
17. Torok, J., Kelsey, C. R., & Salama, J. K. Patterns of Distant Metastases in Surgically Managed Early Stage Non-Small Cell Lung Cancer. In 55th Annual ASTRO Meeting., Atlanta, Georgia., September 22–25, 2013 2013
18. Hasselle, M. D., Haraf, D. J., Rusthoven, K. E., Golden, D. W., Salgia, R., Villaflor, V. M., et al. (2012). Hypofractionated image-guided radiation therapy for patients with limited volume metastatic non-small cell lung cancer. [Research Support, Non-U.S. Gov’t]. Journal of Thoracic Oncology, 7(2), 376–381. doi:10.1097/JTO.0b013e31824166a5.
19. Fong, Y., Fortner, J., Sun, R. L., Brennan, M. F., & Blumgart, L. H. (1999). Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Annals of Surgery, 230(3), 309–318. discussion 318–321.
20. Lussier, Y. A., Khodarev, N. N., Regan, K., Corbin, K., Li, H., Ganai, S., et al. (2012). Oligo- and polymetastatic progression in lung metastasis(es) patients is associated with specific microRNAs. PLoS One, 7(12), e50141. doi:10.1371/journal.pone.0050141.
21. Lussier, Y. A., Xing, H. R., Salama, J. K., Khodarev, N. N., Huang, Y., Zhang, Q., et al. (2011). MicroRNA expression characterizes oligometastasis(es). PLoS One, 6(12), e28650. doi:10.1371/journal.pone.0028650.
22. Niibe, Y., & Hayakawa, K. (2010). Oligometastases and oligo-recurrence: the new era of cancer therapy. Japanese Journal of Clinical Oncology, 40(2), 107–111. doi:10.1093/jjco/hyp167.
23. Gan, G. N., Weickhardt, A. J., Scheier, B., Doebele, R. C., Gaspar, L. E., Kavanagh, B. D., et al. (2014). Stereotactic radiation therapy can safely and durably control sites of extra-central nervous system oligoprogressive disease in anaplastic lymphoma kinase-positive lung cancer patients receiving crizotinib. International Journal of Radiation Oncology, Biology, and Physics, 88(4), 892–898. doi:10.1016/j.ijrobp.2013.11.010.
24. Mehta, N., Mauer, A. M., Hellman, S., Haraf, D. J., Cohen, E. E., Vokes, E. E., et al. (2004). Analysis of further disease progression in metastatic non-small cell lung cancer: implications for locoregional treatment. International Journal of Oncology, 25(6), 1677–1683.
25. De Pas, T. M., de Braud, F., Catalano, G., Putzu, C., Veronesi, G., Leo, F., et al. (2007). Oligometastatic non-small cell lung cancer: a multidisciplinary approach in the positron emission tomographic scan era. Annals of Thoracic Surgery, 83(1), 231–234. doi:10.1016/j.athoracsur.2006.08.017.
26. Ung, Y., Gu, C., Cline, K., Sun, A., & MacRae, R. (2011). An Ontario Clinical Oncology Group (OCOG) randomized trial (PET START) of FDG PET/CT in patients with stage III non-small cell lung cancer (NSCLC): Predictors of overall survival. Journal of Clinical Oncology, 29((suppl; abstr 7018)).
27. Yachida, S., Jones, S., Bozic, I., Antal, T., Leary, R., Fu, B., et al. (2010). Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature, 467(7319), 1114–1117. doi:10.1038/nature09515.
28. Campbell, P. J., Yachida, S., Mudie, L. J., Stephens, P. J., Pleasance, E. D., Stebbings, L. A., et al. (2010). The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature, 467(7319), 1109–1113. doi:10.1038/nature09460.
29. Weichselbaum, R. R., & Hellman, S. (2011). Oligometastases revisited. Nature Reviews. Clinical Oncology, 8(6), 378–382. doi:10.1038/nrclinonc.2011.44.
30. Gupta, G. P., & Massague, J. (2006). Cancer metastasis: building a framework. Cell, 127(4), 679–695. doi:10.1016/j.cell.2006.11.001.
31. Kirkpatrick, J. P., Kelsey, C. R., Palta, M., Cabrera, A. R., Salama, J. K., Patel, P., et al. (2013). Stereotactic body radiotherapy: a critical review for non-radiation oncologists. Cancer. doi:10.1002/cncr.28515.
32. Rusthoven, K. E., Kavanagh, B. D., Burri, S. H., Chen, C., Cardenes, H., Chidel, M. A., et al. (2009). Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases. Journal of Clinical Oncology, 27(10), 1579–1584.
33. Rusthoven, K. E., Kavanagh, B. D., Cardenes, H., Stieber, V. W., Burri, S. H., Feigenberg, S. J., et al. (2009). Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. Journal of Clinical Oncology, 27(10), 1572–1578. doi:10.1200/JCO.2008.19.6329.
34. Torok, J., Wegner, R. E., Burton, S. A., & Heron, D. E. (2011). Stereotactic body radiation therapy for adrenal metastases: a retrospective review of a noninvasive therapeutic strategy. [Case Reports Review]. Future Oncology, 7(1), 145–151. doi:10.2217/fon.10.165.
35. Rudra, S., Malik, R., Ranck, M. C., Farrey, K., Golden, D. W., Hasselle, M. D., et al. (2013). Stereotactic body radiation therapy for curative treatment of adrenal metastases. Technology in Cancer Research & Treatment, 12(3), 217–224. doi:10.7785/tcrt.2012.500320.
36. Milano, M. T., Katz, A. W., Zhang, H., & Okunieff, P. (2012). Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of prospective study. International Journal of Radiation Oncology, Biology, and Physics, 83(3), 878–886. doi:10.1016/j.ijrobp.2011.08.036.
37. Salama, J. K., Hasselle, M. D., Chmura, S. J., Malik, R., Mehta, N., Yenice, K. M., et al. (2012). Stereotactic body radiotherapy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease. Cancer, 118(11), 2962–2970. doi:10.1002/cncr.26611.
38. Kao, J., Chen, C. T., Tong, C. C., Packer, S. H., Schwartz, M., Chen, S. H., et al. (2013). Concurrent sunitinib and stereotactic body radiotherapy for patients with oligometastases: final report of a prospective clinical trial. Targeted Oncology. doi:10.1007/s11523-013-0280-y.
39. Khan, A. J., Mehta, P. S., Zusag, T. W., Bonomi, P. D., Penfield Faber, L., Shott, S., et al. (2006). Long term disease-free survival resulting from combined modality management of patients presenting with oligometastatic, non-small cell lung carcinoma (NSCLC). Radiotherapy and Oncology, 81(2), 163–167.
40. De Ruysscher, D., Wanders, R., van Baardwijk, A., Dingemans, A. M., Reymen, B., Houben, R., et al. (2012). Radical treatment of non-small-cell lung cancer patients with synchronous oligometastases: long-term results of a prospective phase II trial (Nct01282450). Journal of Thoracic Oncology, 7(10), 1547–1555. doi:10.1097/JTO.0b013e318262caf6.
41. Ashworth, A. B., Senan, S., Palma, D. A., Riquet, M., Chan Ahn, Y., Ricardi, U., et al. (2014). An individual patient data metaanalysis of outcomes and prognostic factors after treatment of oligometastatic non-small-cell lung cancer. Clinical Lung Cancer. doi:10.1016/j.cllc.2014.04.003.
42. McCammon, R., Schefter, T. E., Gaspar, L. E., Zaemisch, R., Gravdahl, D., & Kavanagh, B. (2009). Observation of a dose-control relationship for lung and liver tumors after stereotactic body radiation therapy. International Journal of Radiation Oncology, Biology, and Physics, 73(1), 112–118. doi:10.1016/j.ijrobp.2008.03.062.
43. Corbin, K., Ranck, M., Hasselle, M., Golden, D., Partouche, J., Wu, T., et al. (2012). Feasibility and toxicity of hypofractionated image-guided radiotherapy for large volume limited metastatic disease. Practical Radiation Oncology, 3(4), 316–322. doi:10.1016/j.prro.2012.08.006.
44. Solanki, A. A., Weichselbaum, R. R., Appelbaum, D., Farrey, K., Yenice, K. M., Chmura, S. J., et al. (2012). The utility of FDG-PET for assessing outcomes in oligometastatic cancer patients treated with stereotactic body radiotherapy: a cohort study. Radiation Oncology, 7, 216. doi:10.1186/1748-717X-7-216.
45. Palma, D. A., Haasbeek, C. J., Rodrigues, G. B., Dahele, M., Lock, M., Yaremko, B., et al. (2012). Stereotactic ablative radiotherapy for comprehensive treatment of oligometastatic tumors (SABR-COMET): study protocol for a randomized phase II trial. BMC Cancer, 12, 305. doi:10.1186/1471-2407-12-305.
46. Ashworth, A., Rodrigues, G., Boldt, G., & Palma, D. (2013). Is there an oligometastatic state in non-small cell lung cancer? A systematic review of the literature. [Research Support, Non-U.S. Gov’t]. Lung Cancer, 82(2), 197–203. doi:10.1016/j.lungcan.2013.07.026.
47. Parikh, R. B., Cronin, A. M., Kozono, D. E., Oxnard, G. R., Mak, R. H., Jackman, D. M., et al. (2014). Definitive primary therapy in patients presenting with oligometastatic non-small cell lung cancer. International Journal of Radiation Oncology, Biology, and Physics, 89(4), 880–887. doi:10.1016/j.ijrobp.2014.04.007.
48. Lopez Guerra, J. L., Gomez, D., Zhuang, Y., Hong, D. S., Heymach, J. V., Swisher, S. G., et al. (2012). Prognostic impact of radiation therapy to the primary tumor in patients with non-small cell lung cancer and oligometastasis at diagnosis. International Journal of Radiation Oncology, Biology, and Physics, 84(1), e61–e67. doi:10.1016/j.ijrobp.2012.02.054.
49. Ashworth, A. B., Senan, S., Palma, D. A., Riquet, M., Ahn, Y. C., Ricardi, U., et al. (2014). An individual patient data metaanalysis of outcomes and prognostic factors after treatment of oligometastatic non-small-cell lung cancer. Clinical Lung Cancer, 15(5), 346–355. doi:10.1016/j.cllc.2014.04.003.
50. Yano, T., Okamoto, T., Haro, A., Fukuyama, S., Yoshida, T., Kohno, M., et al. (2013). Local treatment of oligometastatic recurrence in patients with resected non-small cell lung cancer. Lung Cancer, 82(3), 431–435. doi:10.1016/j.lungcan.2013.08.006.